Here are the DEF 14A proxy statements from Bio-Rad Laboratories, Inc. (BIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIO filings page.
Bio-Rad Laboratories is asking stockholders to vote at its 2026 annual meeting on director elections, auditor ratification, executive pay, an amended long‑term incentive plan, and a stockholder proposal on its dual‑class structure. The meeting will be held on April 21, 2026 at company headquarters in Hercules, California.
Holders of Class A and Class B shares vote separately to elect two and four directors, respectively, while most other items are decided by a majority of combined voting power present. The board recommends voting for all company proposals, including the advisory say‑on‑pay and the amended 2017 Incentive Award Plan, and against the stockholder proposal seeking changes to the dual‑class capital structure.
The amended equity plan would add to the share reserve and extend the plan’s term to March 18, 2036, with features such as minimum one‑year vesting (with limited exceptions), clawback applicability, no dividends on unvested awards, and a per‑director annual award cap. KPMG LLP is proposed to continue as independent auditor, with 2025 audit fees of $6,192,000 and other 2025 fees of $244,000.